Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.47 |
| ▸ | ME2 | P23368 | 1/20 | 0.46 |
| ▸ | ME1 | P48163 | 1/20 | 0.46 |
| ▸ | ME3 | Q16798 | 1/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15963358 | 0.91 | AVPR1A (0.52) | RAB9APOLBMEN1KMT2AAVPR1A | |
| SCHEMBL15963390 | 0.91 | AVPR1A (0.47) | RAB9APOLBMEN1KMT2AAVPR1A | |
| SCHEMBL15963264 | 0.88 | MAPT (0.53) | RAB9APOLBKMT2AAVPR1AHRH3 | |
| SCHEMBL15963377 | 0.88 | GPR183 (0.48) | RAB9APOLBMEN1KMT2AAVPR1A | |
| SCHEMBL15963510 | 0.88 | AVPR1A (0.52) | MEN1KMT2AAVPR1AHRH3OXTR | |
| SCHEMBL15963365 | 0.88 | AVPR1A (0.55) | RAB9APOLBAVPR1AHRH3 | |
| SCHEMBL15963375 | 0.88 | AVPR1A (0.47) | RAB9APOLBAVPR1AHRH3AVPR2 | |
| SCHEMBL15963395 | 0.87 | HRH3 (0.45) | RAB9APOLBMEN1KMT2AAVPR1A | |
| SCHEMBL15963357 | 0.87 | AVPR1A (0.48) | RAB9APOLBMEN1KMT2AAVPR1A | |
| SCHEMBL15963374 | 0.87 | AVPR1A (0.46) | RAB9APOLBAVPR1AHRH3AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | RAB9A 1258/4885POLB 4865/4885MEN1 1216/4885 |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | RAB9A 1258/4885POLB 4865/4885MEN1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.